Cel-Sci Corporation (CVM) News
Filter CVM News Items
CVM News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
CVM News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest CVM News From Around the Web
Below are the latest news stories about CEL SCI CORP that investors may wish to consider to help them evaluate CVM as an investment opportunity.
CEL-SCI Announces Closing of $5 Million OfferingVIENNA, Va., December 31, 2024--CEL-SCI announces closing of $5 million offering. |
CEL-SCI Announces Pricing of $5 Million Public OfferingVIENNA, Va., December 30, 2024--CEL-SCI announces pricing of $5 million public offering. |
CEL-SCI Announces Proposed Public Offering of Common StockVIENNA, Va., December 27, 2024--CEL-SCI announces proposed public offering of common stock. |
CEL-SCI Highlights Biological Rationale for the Use of Multikine in the Confirmatory Registration Head and Neck Cancer StudyVIENNA, Va., December 12, 2024--CEL-SCI highlights biological rationale for the use of Multikine in the Confirmatory Registration Head and Neck Cancer Study. |
CVM: CRO Selected for Registrational TrialBy John Vandermosten, CFA NYSE:CVM READ THE FULL CVM RESEARCH REPORT CEL-SCI Corporation (NYSE:CVM) has made progress advancing the prerequisites for the upcoming registrational trial, selecting the contract research organization (CRO) that will run it and coming to an agreement with the FDA on which biomarkers are appropriate for selecting patients. The view of oncologists as expressed by the |
U.S. FDA and CEL-SCI Agree on Use of PD-L1 Biomarker to Select Head and Neck Cancer Patients for Marketing Registration Study to Commence Q1 2025VIENNA, Va., November 07, 2024--U.S. FDA and CEL-SCI Agree on Use of PD-L1 Biomarker to Select Head and Neck Cancer Patients for Marketing Registration Study to Commence Q1 2025. |
FDA’s Oncologic Drugs Advisory Committee Decision on Checkpoint Inhibitors Substantiates Potential of CEL-SCI’s Multikine® to Address Major Treatment Gap for PD-L1 Negative Cancer PatientsVIENNA, Va., October 22, 2024--FDA’s ODAC decision on checkpoint inhibitors substantiates potential of Multikine to address major treatment gap for PD-L1 negative cancer patients. |
CEL-SCI Selects Ergomed as CRO as it Gears Up for Confirmatory FDA Registration Study of Multikine® in Head and Neck CancerVIENNA, Va., October 01, 2024--CEL-SCI selects Ergomed as CRO as it gears up for Confirmatory FDA Registration Study of Multikine in Head and Neck Cancer. |
CEL-SCI’s Multikine® Increased 5-Year Survival Rate to 82.6% in Locally Advanced Resectable Head & Neck Cancer Patients Who Were Deemed to be in the Treatment Group for Surgery and RadiationVIENNA, Va., September 16, 2024--CEL-SCI’s Multikine Increased 5-Year Survival Rate in Locally Advanced Resectable Head & Neck Cancer Patients Deemed to be in the Treatment Group. |
CEL-SCI to Present New Data for Multikine® Head & Neck Cancer Immunotherapy at the European Society for Medical Oncology 2024 CongressVIENNA, Va., September 10, 2024--CEL-SCI to present new data for Multikine head & neck cancer immunotherapy at the European Society for Medical Oncology 2024 Congress. |